Cantor Fitzgerald Estimates REGN FY2025 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Regeneron Pharmaceuticals in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer anticipates that the biopharmaceutical company will post earnings per share of $38.93 for the year. Cantor Fitzgerald has a “Neutral” rating and a $1,015.00 price objective on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $37.72 per share.

A number of other research firms have also recently issued reports on REGN. Piper Sandler cut their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. Morgan Stanley decreased their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Evercore ISI cut their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Finally, Oppenheimer decreased their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Trading Down 1.1 %

Shares of NASDAQ REGN opened at $680.03 on Wednesday. Regeneron Pharmaceuticals has a 12-month low of $666.25 and a 12-month high of $1,211.20. The company has a market cap of $74.73 billion, a price-to-earnings ratio of 16.83, a price-to-earnings-growth ratio of 1.61 and a beta of 0.10. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock’s 50 day simple moving average is $733.06 and its 200 day simple moving average is $943.95.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Mizuho Securities USA LLC increased its stake in Regeneron Pharmaceuticals by 625.5% in the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock worth $62,382,000 after purchasing an additional 51,162 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after acquiring an additional 2,828 shares in the last quarter. Simplify Asset Management Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 50.8% during the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock valued at $10,082,000 after acquiring an additional 3,231 shares during the period. Catalytic Wealth RIA LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $1,334,000. Finally, Daiwa Securities Group Inc. boosted its stake in Regeneron Pharmaceuticals by 12.3% in the 3rd quarter. Daiwa Securities Group Inc. now owns 20,384 shares of the biopharmaceutical company’s stock worth $21,428,000 after purchasing an additional 2,234 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.